Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 22, 2017
What is the patent landscape for Targiniq, and when can generic versions of Targiniq launch?
Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twenty patents protecting this drug.| Patents: | 20 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | TARGINIQ at DailyMed |
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,674,800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | ► Subscribe | |||||||||||||||||||||||||||
| 7,683,072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | ► Subscribe | |||||||||||||||||||||||||||
| 6,375,957 | Opioid agonist/opioid antagonist/acetaminophen combinations | ► Subscribe | |||||||||||||||||||||||||||
| 7,749,542 | Opioid agonist/antagonist combinations | ► Subscribe | |||||||||||||||||||||||||||
| 9,480,685 | Abuse-resistant controlled-release opioid dosage form | ► Subscribe | |||||||||||||||||||||||||||
| 7,674,799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | ► Subscribe | |||||||||||||||||||||||||||
| 7,419,686 | Opioid agonist/antagonist combinations | ► Subscribe | |||||||||||||||||||||||||||
| 7,129,248 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | ► Subscribe | |||||||||||||||||||||||||||
| 7,172,767 | Opioid agonist / antagonist combinations | ► Subscribe | |||||||||||||||||||||||||||
| 9,655,855 | Matrix for sustained, invariant and independent release of active compounds | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| South Korea | 100417489 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2008499 | ► Subscribe | |||||||||||||||||||||||||||
| Slovenia | EP1041987 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2362282 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 20040098050 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 20140021716 | ► Subscribe | |||||||||||||||||||||||||||
| Germany | 602005026786 | ► Subscribe | |||||||||||||||||||||||||||
| Cyprus | 1117228 | ► Subscribe | |||||||||||||||||||||||||||
| Hungary | E031668 | ► Subscribe | |||||||||||||||||||||||||||
| Denmark | 1492506 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00619 | Netherlands | ► Subscribe | PRODUCT NAME: EEN COMBINATIE VAN OXYCODON ALS COMPONENT A EN NALOXON ALS COMPONENT B IN ALLE VORMEN ZOALS DEZE DOOR HET BASIS OCTROOI ONDER BESCHERMING WORDEN GESTELD; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 20060530 | ||||||||||||||||||||||||||
| 2013 00052 | Denmark | ► Subscribe | PRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530 | ||||||||||||||||||||||||||
| 292 | Luxembourg | ► Subscribe | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE | ||||||||||||||||||||||||||
| 2013000082 | Germany | ► Subscribe | PRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,737 others who get our Drug Patent Expiration Alerts:
